Literature DB >> 8518060

Anticardiolipin antibodies in ischaemic heart disease: marker or myth?

K V Phadke1, R A Phillips, D T Clarke, M Jones, P Naish, P Carson.   

Abstract

OBJECTIVES: To assess the incidence and significance of anticardiolipin antibodies after myocardial infarction and in unstable angina.
DESIGN: A prospective study of all patients under 60 admitted to the coronary care unit over a 12 month period with a diagnosis of acute myocardial infarction who were followed up for a further 12 months. Patients admitted with unstable angina were similarly assessed but not followed up. Anticardiolipin antibody concentrations were compared with those of age matched controls.
SETTING: A district general hospital. PATIENTS: 307 patients with acute myocardial infarction and 160 patients with unstable angina.
RESULTS: Anticardiolipin antibody concentrations in the two patient groups did not differ significantly from those in the control groups. Antibody concentrations were not related to a history of angina or myocardial infarction nor were they related to subsequent cardiovascular complications.
CONCLUSION: This study shows no significant association between anticardiolipin antibody concentrations and either myocardial infarction or unstable angina.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8518060      PMCID: PMC1025099          DOI: 10.1136/hrt.69.5.391

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  10 in total

1.  Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke.

Authors:  K E Sletnes; P Smith; M Abdelnoor; H Arnesen; F Wisløff
Journal:  Lancet       Date:  1992-02-22       Impact factor: 79.321

2.  Myocardial infarction in a young man with systemic lupus erythematosus, deep vein thrombosis, and antibodies to phospholipid.

Authors:  R A Asherson; I R Mackay; E N Harris
Journal:  Br Heart J       Date:  1986-08

3.  Standardising the anti-cardiolipin antibody test.

Authors:  E N Harris; G R Hughes
Journal:  Lancet       Date:  1987-01-31       Impact factor: 79.321

4.  Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events.

Authors:  A Hamsten; R Norberg; M Björkholm; U de Faire; G Holm
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

5.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

6.  Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results.

Authors:  S Loizou; J D McCrea; A C Rudge; R Reynolds; C C Boyle; E N Harris
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

Review 7.  Antiphospholipid antibodies--autoantibodies with a difference.

Authors:  E N Harris; R A Asherson; G R Hughes
Journal:  Annu Rev Med       Date:  1988       Impact factor: 13.739

8.  Anti-mitochondrial type M5 and anti-cardiolipin antibodies in autoimmune disorders: studies on their association and cross-reactivity.

Authors:  P L Meroni; E N Harris; A Brucato; A Tincani; W Barcellini; A Vismara; G Balestrieri; G R Hughes; C Zanussi
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

9.  Anti-cardiolipin antibodies in ischaemic heart disease.

Authors:  P Klemp; R C Cooper; F J Strauss; E R Jordaan; J Z Przybojewski; N Nel
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

10.  Coronary artery bypass graft failure--an autoimmune phenomenon?

Authors:  K E Morton; T P Gavaghan; S A Krilis; G E Daggard; D W Baron; J B Hickie; C N Chesterman
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

  10 in total
  6 in total

Review 1.  Anticardiolipin antibodies and cardiovascular disease.

Authors:  K W Muir
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

2.  Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.

Authors:  Carolyn Neville; Joyce Rauch; Jeannine Kassis; Erika R Chang; Lawrence Joseph; Martine Le Comte; Paul R Fortin
Journal:  Thromb Haemost       Date:  2003-07       Impact factor: 5.249

3.  Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus.

Authors:  A Doria; Y Shoenfeld; R Wu; P F Gambari; M Puato; A Ghirardello; B Gilburd; S Corbanese; M Patnaik; S Zampieri; J B Peter; E Favaretto; L Iaccarino; Y Sherer; S Todesco; P Pauletto
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

4.  Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis.

Authors:  Iván Palomo; Jaime Pereira; Marcelo Alarcón; Marcela Vásquez; Carmen Pinochet; María T Vélez; Jorge Sandoval; Gloria Icaza; Silvia Pierangeli
Journal:  Clin Rheumatol       Date:  2004-01-31       Impact factor: 2.980

Review 5.  Antiphospholipid syndrome; its implication in cardiovascular diseases: a review.

Authors:  Ioanna Koniari; Stavros N Siminelakis; Nikolaos G Baikoussis; Georgios Papadopoulos; John Goudevenos; Efstratios Apostolakis
Journal:  J Cardiothorac Surg       Date:  2010-11-03       Impact factor: 1.637

6.  The clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study.

Authors:  Faruk Ertaș; Oznur Can; Halit Acet; Mert Ozbakkaloglu
Journal:  Postepy Kardiol Interwencyjnej       Date:  2013-11-18       Impact factor: 1.426

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.